A TRIAL has found that the commonly used antibiotics, azithromycin and doxycycline, do not reduce recovery time for COVID-19 patients in the community.
The ‘Platform Randomised trial of Interventions against COVID-19 In older people’ (PRINCIPLE) trial was funded by UK Research and Innovation (UKRI).
Azithromycin and doxycycline are two commonly used antibiotics. They were investigated as separate treatments in the trial to see if they might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission.
Both drugs are being used by some doctors in the hope of treating COVID-19 in the early stages of the illness.
Interim analyses of both the azithromycin and doxycycline arms of the trial, concluded that there is no beneficial effect in patients aged over 50 who are treated with either antibiotic at home in the early stages of COVID-19.
Neither treatment reduced the time taken for people to first report that they feel recovered sufficiently to achieve meaningful clinical benefit.
Professor Chris Butler from the University of Oxford and co-lead of the PRINCIPLE trial, said: “Azithromycin and doxycycline have anti-inflammatory, anti-bacterial and possibly anti-viral effects, and so were considered as potential treatments for COVID-19 in the community.
“While we are completing the analysis of the full range of study outcomes, and in different patient groups, our findings show that a three-day course of azithromycin or a seven-day course of doxycycline has no important clinical benefit in terms of the time taken to feeling recovered, and so will not help most patients with COVID-19 in the early stages their illness.
“These are two important findings, as both azithromycin and doxycycline have been used for treating COVID-19 in the community even in the absence of suspected bacterial pneumonia, so this practice should now be re-considered – particularly because overuse of antibiotics in the community can fuel the emergence of antimicrobial resistance.”
Professor Richard Hobbs another co-lead of the trial at Oxford, said: “While it is disappointing that neither azithromycin nor doxycycline speed-up recovery for those with COVID-19 in the community, these are both important findings which will reduce the use of ineffective antibiotics for this illness.
“This finding shows the importance of doing rigorous clinical trials in real-world settings before treatments are rolled out on a wide scale. Widespread use of treatment should not be based on laboratory studies and opinion alone.
“We remain incredibly grateful for the huge efforts from many patients, GP practices and other organisations in delivering this national, flagship primary care study in these challenging times.”